Jag Capital Management Lowers stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Jag Capital Management reduced its stake in Edwards Lifesciences Corp by 3.89% during the most recent quarter end. The investment management company now holds a total of 126,220 shares of Edwards Lifesciences Corp which is valued at $13,410,875 after selling 5,110 shares in Edwards Lifesciences Corp , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.Edwards Lifesciences Corp makes up approximately 2.57% of Jag Capital Management’s portfolio.

Other Hedge Funds, Including , Wealthtrust-arizona boosted its stake in EW in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 93 shares of Edwards Lifesciences Corp which is valued at $9,881. Edwards Lifesciences Corp makes up approx 0.01% of Wealthtrust-arizona’s portfolio.First Quadrant L Pca boosted its stake in EW in the latest quarter, The investment management firm added 700 additional shares and now holds a total of 63,300 shares of Edwards Lifesciences Corp which is valued at $6,754,743. Edwards Lifesciences Corp makes up approx 0.14% of First Quadrant L Pca’s portfolio.Telemus Capital boosted its stake in EW in the latest quarter, The investment management firm added 2,000 additional shares and now holds a total of 13,000 shares of Edwards Lifesciences Corp which is valued at $1,387,230. Edwards Lifesciences Corp makes up approx 0.16% of Telemus Capital’s portfolio.Livforsakringsbolaget Skandia Omsesidigt boosted its stake in EW in the latest quarter, The investment management firm added 5,900 additional shares and now holds a total of 28,580 shares of Edwards Lifesciences Corp which is valued at $3,022,335. Edwards Lifesciences Corp makes up approx 0.13% of Livforsakringsbolaget Skandia Omsesidigt’s portfolio.

Edwards Lifesciences Corp opened for trading at $106.44 and hit $107.13 on the upside on Wednesday, eventually ending the session at $106.71, with a gain of 0.76% or 0.8 points. The heightened volatility saw the trading volume jump to 10,61,682 shares. Company has a market cap of $22,597 M.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Edwards Lifesciences Corp was Initiated by Guggenheim to “Neutral” on Jun 9, 2016. Company shares were Reiterated by Canaccord Genuity on May 23, 2016 to “Buy”, Firm has raised the Price Target to $ 132 from a previous price target of $123 .Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $110 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.